1. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors. (1st January 2021) Authors: Burne, Rebecca; Balu, Sanjeev; Guérin, Annie; Bungay, Rebecca; Sin, Roxana; Paul, Mary Lisha Journal: Journal of medical economics Issue: Volume 24:Number 1(2021) Page Start: 806 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. (3rd October 2017) Authors: McBride, Ali; Campbell, Kim; Bikkina, Mohan; MacDonald, Karen; Abraham, Ivo; Balu, Sanjeev Journal: Journal of medical economics Issue: Volume 20:Number 10(2017) Page Start: 1083 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim. (4th July 2018) Authors: Grewal, Simrun; Ramsey, Scott; Balu, Sanjeev; Carlson, Josh J. Journal: Expert review of pharmacoeconomics & outcomes research Issue: Volume 18:Number 4(2018) Page Start: 447 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference pegfilgrastim. (2nd August 2020) Authors: McBride, Ali; Wang, Weijia; Campbell, Kim; Balu, Sanjeev; MacDonald, Karen; Abraham, Ivo Journal: Journal of medical economics Issue: Volume 23:Number 8(2020) Page Start: 856 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Evaluation of access to care issues in patients with breast cancer. (1st January 2021) Authors: Brown, Carolyn M.; Richards, Kristin M.; Vohra, Yogesh; Kanu, Chisom; Stevens, Laura; Sasane, Rahul; Balu, Sanjeev; McAneny, Barbara Journal: Journal of medical economics Issue: Volume 24:Number 1(2021) Page Start: 38 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. (October 2017) Authors: McBride, Ali; Balu, Sanjeev; Campbell, Kim; Bikkina, Mohan; MacDonald, Karen; Abraham, Ivo Journal: Future oncology Issue: Volume 13:Number 25(2017) Page Start: 2285 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. (October 2017) Authors: McBride, Ali; Balu, Sanjeev; Campbell, Kim; Bikkina, Mohan; MacDonald, Karen; Abraham, Ivo Journal: Future oncology Issue: Volume 13:Number 25(2017) Page Start: 2285 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma. (2nd January 2020) Authors: McBride, Ali; Krendyukov, Andriy; Mathieson, Nicola; Campbell, Kim; Balu, Sanjeev; Natek, Maja; MacDonald, Karen; Abraham, Ivo Journal: Journal of medical economics Issue: Volume 23:Number 1(2020) Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Impact of 5-HT3 RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting. (August 2011) Authors: Schwartzberg, Lee; Jackson, James; Jain, Gagan; Balu, Sanjeev; Buchner, Deborah Journal: Expert review of pharmacoeconomics & outcomes research Issue: Volume 11:Number 4(2011) Page Start: 481 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Impact of 5-HT3 RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting. (August 2011) Authors: Schwartzberg, Lee; Jackson, James; Jain, Gagan; Balu, Sanjeev; Buchner, Deborah Journal: Expert review of pharmacoeconomics & outcomes research Issue: Volume 11:Number 4(2011) Page Start: 481 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗